Factors affecting outcome in renal cell carcinoma

Current Opinion in Urology

Volumn 20, Issue 5, 2010, Pages 355-360

  Sun, Maxine ^a   Shariat, Shahrokh F ^b   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

outcome; prognostic factors; renal cell carcinoma

Indexed keywords

BIOLOGICAL FACTOR; CYTOKINE; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; SUNITINIB; VASCULOTROPIN;

ADVANCED CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; KIDNEY CARCINOMA; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; REVIEW;

CARCINOMA, RENAL CELL; HEALTH STATUS INDICATORS; HUMANS; KIDNEY NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77955468064     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32833c7b19     Document Type: Review

References (92)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335:865-875.
2. Karakiewicz PI, Briganti A, Chun FK-H, et al. Multiinstitutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25:1316-1322.
3. Karakiewicz PI, Trinh Q-D, Bhojani N, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 2007; 51:1616-1624.
4. LughezzaniG, Jeldres C, Isbarn H, et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol 2009; 182:1287-1293.
5. Zini L, Capitanio U, Perrotte P, et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009; 73:342-346.
6. Karakiewicz PI, Jeldres C, Suardi N, et al. Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J 2008; 2:610-617.
7. Jeon HG, Jeong IG, Lee JH, et al. Prognostic value of body mass index in Korean patients with renal cell carcinoma. J Urol 2010; 183:448-454.
8. Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010; 28:311-317.
9. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19:1649-1657.
10. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559-4566.
11. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res 2004; 10 (18 Pt 2):6302S-6303S.
12. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296.
13. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
14. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-841.
15. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005; 174:466-472; discussion 472; quiz 801.
16. Elson P, Witte R, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48:7310-7313.
17. Karakiewicz PI, Trinh Q-D, De La Taille A, et al. ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival. Eur J Cancer (Oxford, England: 1990) 2007; 43:1023-1029.
18. Leibovich B, Lohse C, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010; 183:1309-1315.
19. Kwak C, Park Y, Jeong C, et al. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 2007; 95:317-323.
20. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25:275-284.
21. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168:2395-2400.
22. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173:48-51.
23. Frank I, Blute ML, Cheville JC, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003; 170 (6 Pt 1):2225-2232.
24. Sun M, Lughezzani G, Jeldres C, et al. A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. Eur Urol 2009; 56:753-890.
25. Karakiewcz P, Lewinshtein DJ, Chun F, et al. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol 2006; 50:521-528.
26. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174:1759-1763.
27. Isbarn H, Patard J, Lughezzani G, et al. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma. Urology 2009; 75:1378-1384.
28. Katz MD, Serrano MF, Grubb RL, et al. Percentage microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. J Urol 2010; 183:909-914.
29. Klatte T, Said JW, de Martino M, et al. Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol 2009; 181:1558-1564.
30. Lam JS, Shvarts O, Said JW, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 2005; 103:2517-2525.
31. Karakiewicz PI, Hutterer GC, Trinh Q-D, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007; 110:1241-1247.
32. Iimura Y, Saito K, Fujii Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009; 181:1004-1012.
33. Escudier B, Choueiri TK, Oudard S, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007; 178:1901-1905.
34. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22:454-463.
35. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
36. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007; 356:125-134.
37. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa- 2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet 2007; 370:2103-2111.
38. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
39. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
40. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-1068.
41. Cindolo L, Chiodini P, Gallo C, et al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 2008; 113:65-71.
42. Cindolo L, Patard J-J, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005; 104:1362-1371.
43. Ficarra V, Novara G, Galfano A, et al. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int 2009; 103:165-170.
44. Galfano A, Novara G, Iafrate M, et al. Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 2008; 80:113-123.
45. Liu Z, Lv J, Ding K, Fu Q, Cao Q, Wang F. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience. Int J Urol 2009; 16:268-273.
46. Patard J-J, Leray E, Cindolo L, et al. Multiinstitutional validation of a symptom based classification for renal cell carcinoma. J Urol 2004; 172:858-862.
47. Tan M-H, Kanesvaran R, Li H, et al. Comparison of the UCLA Integrated Staging System and the Leibovich Score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. Urology 2010; 75:1365-1370.
48. Karakiewicz PI, Suardi N, Capitanio U, et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2009; 55:287-295. A contemporary and accurate pretreatment prognostic model for prediction of RCC-specific mortality from 1-10 years after nephrectomy.
49. Karakiewicz PI, Suardi N, Capitanio U, et al. Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol 2009; 182:2607-2612. Conditional nomogram for predicting RCC-specific mortality that allows consideration of the length of survivorship.
50. Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for nonmetastatic renal cell carcinoma. BJU Int 2003; 92:901-905.
51. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 2001; 58:141-145.
52. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 2008; 179:2146-2151.
53. Leibovich BC, Han K-R, Bui MHT, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98:2566-2575.
54. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166:63-67.
55. Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009; 115:2092-2103.
56. Institute NC. Dictionary of cancer terms; 2010. www.cancer.gov.
57. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004; 10:5464-5471.
58. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005; 173:1496-1501.
59. Ransohoff D, Gourlay M. Sources of bias in specimens for research about molecular markers for cancer. J Clin Orthod 2010; 28:698-704.
60. Negrier S, Gomez F, Douillard J-Y, et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothe' rapie. World J of urol 2005; 23:161-165.
61. Atzpodien J, Royston P, Wandert T, Reitz M,Group D-GCRCC-IT. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88:348-353.
62. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27:4709-4717.
63. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24:1997-2005.
64. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110:543-550.
65. Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794-5799. A prognostic model for overall survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy.
66. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
67. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759.
68. van der Veldt AAM, Meijerink M, van den Eertwegn A, Haanen J, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010; 102:803-809.
69. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113:1552-1558.
70. Patil S, Figlin RA, Hutson T, et al. Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Paper presented at ASCO2009. J Clin Oncol 2009; 27:15s [abstract 5042].
71. Rini BI, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006; 98:756-762.
72. Hutson T, Davis I, Machiels J, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. Paper presented at ASCO2008. J Clin Oncol 2008; 26 [abstract 504].
73. Patel P, Chadalavada R, Ishill N, et al. Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). Paper presented at 2008 ASCO Annual Meeting 2008. J Clin Oncol 2008; 26 [abstract 5008].
74. Figlin RA, de Souza P,McDermott D, et al. Analysis of PTENand HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009; 115:3651-3660.
75. Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Cancer Rev 2007; 1:85-91.
76. Sabatino M, Kim-Schulze S, Pnaelli M, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin- 2 therapy. JCO 2009; 27:2645-2652.
77. Agency BCC. An exploratory correlative study of biomarkers in patients with metastatic renal cell carcinoma who have progressed after sunitinib therapy. NCT005387722010; http://clinicaltrials.gov/ct2/show/NCT00538772?term= NCT00538772&rank=1.
78. Paris APHd. Biological, pathological and imagery markers in the first-line treatment of metastatic clear-cell renal cell carcinoma (PREINSUT). NCT00930345 2010; http://clinicaltrials.gov/ct2/show/NCT00930345?term= NCT00930345&rank=1.
79. Health UNIo. The high-dose aldesleukin (IL-2) "Select" trial for patients with metastatic renal cell carcinoma (SELECT). 2010; http://clinicaltrials.gov/ct2/ show/NCT00554515, 2010.
80. Health UNIo. Monoclonal antibody therapy (Rencarex1) in treating patients who have undergone surgery for nonmetastatic kidney cancer; 2010.
81. Etienne CHUdS. Serum CA9 level as biological marker of the treatment response in metastatic renal cell cancer (CA9CRM). NCT00942058 2010; http://clinicaltrials.gov/ct2/show/NCT00942058?term=NCT00942058 &rank=1.
82. Hainsworth JD, Spigel DR, Burris HA, Waterhouse D, Clark BL, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010; 28:2131-2136.
83. Di Lorenzo G, Carteni G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009; 27:4469-4474.
84. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-67.
85. Gerullis H, Bergmann L, Maute L, et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2010; 27:373-378.
86. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2010; 182:29-34.
87. Escudier B, Goupil MG, Massard C, Fizazi K. Sequential therapy in renal cell carcinoma. Cancer 2009; 115 (10 Suppl):2321-2326.
88. Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factortargeted therapy. Urology 2010. [Epub ahead of print]
89. Wyeth. Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. NCT00474786 2010; http://clinicaltrials.gov/ct2/show/NCT00474786?term=NCT00474786 &rank=1.
90. Pfizer. Axitinib (AG 013736) as second line therapy for metastatic renal cell cancer. NCT00678392 2010; http://clinicaltrials.gov/ct2/show/NCT 00678392? term=NCT00678392&rank=1.
91. GmbHS. Sequential study to treat renal cell carcinoma. NCT00732914 2010; http://clinicaltrials.gov/ct2/show/NCT00732914?term=NCT00732914 &rank=1.
92. Pharmaceuticals N. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3). NCT00903175 2010; http://clinical trials.gov/ct2/show/NCT00903175?term=NCT00903175&rank=1.